Sat.Jul 20, 2024 - Fri.Jul 26, 2024

article thumbnail

Ipsen builds again, licensing Day One glioma drug

pharmaphorum

Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a drug for common brain cancer glioma from Day One Biopharmaceuticals.

105
105
article thumbnail

Sinking prices for generic meds a major factor in US shortage crisis: report

Fierce Pharma

As lawmakers and industry groups seek to get a handle on U.S. | As lawmakers and industry groups seek to get a handle on U.S. drug shortages, a new white paper from German market analytics firm QYOBO supports the thesis that disproportionately low prices for generic medicines can make it difficult for drugmakers to keep supplies afloat.

Medicine 321
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How NVIDIA grew with the healthcare market instead of pushing into it

Pharmaceutical Technology

As the use of AI soared across healthcare, NVIDIA fit the bill in providing the necessary technology – and its stock tells the same story.

article thumbnail

GenAI is a Goal but Not the Destination in Healthcare

MedCity News

GenAI will help healthcare reach its destination of efficiency and superior outcomes, but we can’t lose sight of the need for human touch, quality interactions and data to navigate us forward. The post GenAI is a Goal but Not the Destination in Healthcare appeared first on MedCity News.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Study suggests targeting amyloid beta production could be promising in AD

PharmaTimes

The neurodegenerative disease is currently the most common cause of dementia

131
131
article thumbnail

Enhertu stalls as AstraZeneca, Daiichi navigate 'harder yards' for ADC star

Fierce Pharma

Among AstraZeneca’s growth drivers with $5 billion or more in peak sales potential, the company is counting on Daiichi Sankyo-partnered Enhertu to chart new territory. | Among AstraZeneca's growth drivers with $5 billion or more in peak sales potential, the company is counting on Daiichi Sankyo-partnered Enhertu to chart new territory. And stalling sales underscore the challenges facing the HER2 drug.

Sales 300

More Trending

article thumbnail

NCPA, Providers File Lawsuit Against UHG Over Change Healthcare Cyberattack

MedCity News

The National Community Pharmacists Association and providers argued that Change Healthcare didn’t take the needed precautions against the cyberattack that happened earlier this year. The post NCPA, Providers File Lawsuit Against UHG Over Change Healthcare Cyberattack appeared first on MedCity News.

article thumbnail

How to Get Medical Device Sales Jobs with No Experience?

David Bagga

Medical Device Sales Academy How to Get Medical Device Sales Jobs with No Experience? Medical device sales become one of the best career options today. More and more people want to crack medical device sales jobs and earn a better living. However, things can seem challenging without prior experience in this field. You must wonder if you […] The post How to Get Medical Device Sales Jobs with No Experience?

Sales 130
article thumbnail

Pfizer quickly expands its hemophilia B gene therapy's reach with EU approval

Fierce Pharma

Three months after bagging FDA approval, Pfizer’s hemophilia B gene therapy has been cleared to expand its reach across the pond. | The company's first gene therapy will debut in Europe as Durveqtix. In the U.S., the drug is approved under the brand name Beqvez.

FDA 299
article thumbnail

In shock move, EU panel rejects Alzheimer's drug Leqembi

pharmaphorum

CHMP recommends against approval of Eisai, Biogen's Alzheimer's disease therapy Leqembi, saying side effects outweigh its benefits

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Healthcare’s Failure of AI Imagination

MedCity News

The dynamics of care delivery have already begun to shift, whether healthcare likes it or not. And it’s an opportunity to collaborate alongside healthcare consumers to shape what will be. The post Healthcare’s Failure of AI Imagination appeared first on MedCity News.

article thumbnail

What is A Good Base Salary in Sales?

David Bagga

Medical Device Sales Academy What is A Good Base Salary in Sales? In the competitive sales world, salaries vary widely depending on industry, experience, and location. Knowing the salary terrain can be essential to those curious to join medical device sales and to assist in making possible career decisions. Selling medical devices can be a […] The post What is A Good Base Salary in Sales?

Sales 130
article thumbnail

Agilent Technologies lays out $925M to acquire Canadian specialty CDMO Biovectra

Fierce Pharma

After changing hands several times throughout the 2010s, Canadian specialty contract development and manufacturing organization (CDMO) Biovectra has agreed to fly the Agilent flag. | Agilent has revealed that it’s signed a definitive agreement to acquire Biovectra for $925 million through a mix of cash and debt financing. The deal is expected to close this year.

article thumbnail

Welsh rugby great fronts UK atrial fibrillation campaign

pharmaphorum

Former Welsh rugby union captain Alum Wyn Jones is the face of a new awareness campaign launching in the UK today to draw attention to atrial fibrillation (AF), an irregular and potentially life-threatening heart rhythm abnormality.

115
115
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Earning Trust in Neurotech

MedCity News

By prioritizing user-centric design, responsible data practices, and evidence-based solutions neurotech companies can not only drive user adoption but also foster long-term brand loyalty. The post Earning Trust in Neurotech appeared first on MedCity News.

124
124
article thumbnail

Which Medical Sales Job Pays the Most?

David Bagga

Medical Device Sales Academy Which Medical Sales Job Pays the Most? Pharma and medical device firms are also responsible for healthcare innovation and offer some of the highest-paying sales jobs. They are relevant to different economic industries. They act as a bridge between health professionals and medical device development. These skilled professionals use innovative medical […] The post Which Medical Sales Job Pays the Most?

article thumbnail

AbbVie boosts profit outlook as Humira successors branch into gastroenterology market

Fierce Pharma

With a new chief at the helm and higher profit projections in sight, AbbVie is entering a “new chapter," CEO Robert Michael told analysts Thursday. | Skyrizi's recent ulcerative colitis nod sets it up as a first-line option, while Rinvoq is poised to handle later lines.

Marketing 290
article thumbnail

Study points to route for 'one and done' flu vaccine

pharmaphorum

Scientists at OHSU in the US have developed a universal form of influenza vaccine that they say could protect against all strains of the virus

113
113
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

In This Round, Humans 1, AI LLMs 0

MedCity News

Anthropic’s Claude3-Opus performed better than GPT-4, but both fell short of humans on a test of objective medical knowledge. The study was conducted by a firm developing LLMs specifically for healthcare that claim to be incorporating peer-reviewed sources of information. The post In This Round, Humans 1, AI LLMs 0 appeared first on MedCity News.

article thumbnail

Study reveals blood proteins predict risk of developing many diverse diseases

PharmaTimes

Researchers predicted the onset of 67 diseases, out-performing current standard models

Pharma 109
article thumbnail

FDA advisers, frustrated by AZ's Imfinzi design, call for revamp of perioperative lung cancer trials

Fierce Pharma

The FDA’s Oncologic Drugs Advisory Committee (ODAC) has unanimously called for a revamp of perioperative clinical trial designs in resectable non-small cell lung cancer (NSCLC) to include assessmen | In a discussion prompted by AstraZeneca's application for Imfinzi, the FDA’s Oncologic Drugs Advisory Committee (ODAC) has unanimously called for a revamp of perioperative clinical trial designs in resectable non-small cell lung cancer.

FDA 290
article thumbnail

Agilent builds its CDMO arm with $925m Biovectra buy

pharmaphorum

Agilent has boosted its contract development and manufacturing organisation (CDMO) capacity with a $925 million deal to buy Biovectra, a Canadian provider of fill-and-finish services and active pharmaceutical ingredients (APIs).It's a statement of intent from Agilent, whose primary business is lab instrumentation and equipment, suggesting that it intends to grow the outsourcing side of its business, which is currently focused on the production of oligonucleotide and peptide medicines.

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Credit Monitoring Won’t Save You: The True Fallout of the Change Healthcare Hack is Just Beginning

MedCity News

The attack has given detailed dossiers on millions of lives to criminals, employers, enemies and anyone with the means and motivation to exploit them. This isn’t just another data breach, it’s a healthcare catastrophe — and it’s being inexplicably downplayed. The post Credit Monitoring Won’t Save You: The True Fallout of the Change Healthcare Hack is Just Beginning appeared first on MedCity News.

article thumbnail

New study shows wearable trackers provide clinical use for heart disease patients

PharmaTimes

Cardiovascular disease, including coronary heart disease, currently affects around seven million people in the UK

Patients 109
article thumbnail

Amid Eylea clash, Roche's Vabysmo keeps climbing despite a slowdown in its momentum

Fierce Pharma

While Roche touted sales and market share increases for eye disease drug Vabysmo on Thursday, there is evidence of a slowdown of its momentum as it battles Regeneron and Bayer’s powerhouse Eylea fr | While Roche touted sales and market share increases for eye disease drug Vabysmo on Thursday, there is evidence of a slowdown of its momentum as it battles Regeneron and Bayer’s powerhouse Eylea.

Sales 290
article thumbnail

PBMs under the cosh at House hearing on drug pricing

pharmaphorum

The top three pharmacy benefit managers in the US felt the heat at a hearing of the House Oversight Committee, as lawmakers grilled executives over their business practices and accused them of monopolising the supply chain.

article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

Fueled With $100M, Autobahn Therapeutics Gears Up for Depression Drug Clinical Trials

MedCity News

Autobahn Therapeutics’ platform technology enables small molecules to selectively hit targets in the brain. In addition to a lead program ready for Phase 2 testing in two types of depression, the startup has a preclinical molecule with potential applications in neuroinflammatory disorders such as multiple sclerosis. The post Fueled With $100M, Autobahn Therapeutics Gears Up for Depression Drug Clinical Trials appeared first on MedCity News.

Leads 122
article thumbnail

New gut microbiome atlas could offer better treatment for digestive disorders

PharmaTimes

The new Human Gut Microbiome Atlas could help treat conditions including IBS and AMR

107
107
article thumbnail

Eisai and Biogen's Alzheimer's med Leqembi turned down in Europe

Fierce Pharma

Despite winning approvals in a range of countries like the U.S., China, Japan and Israel, Eisai and Biogen’s anti-amyloid Alzheimer’s disease med Leqembi has come up short in the eyes of European r | Despite winning approvals in a range of countries like the U.S., China and Japan, Eisai and Biogen’s anti-amyloid Alzheimer’s disease med Leqembi has come up short in the eyes of European regulators.

289
289
article thumbnail

Study finds wearables deliver key insights in heart disease

pharmaphorum

Consumer wearables have shown a benefit when used to monitor treatment responses in patients with atrial fibrillation and heart failure.

Patients 111
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time